# US 2004/0203155 A1 · Methods for transfecting T cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0203155 A1
- Document ID: US20040203155A1
- Status: Published application
- Kind: A1
- Application number: 10/828,481
- Filed: 2004-04-20
- Published: 2004-10-14
- Earliest claimed: 1995-05-04
- Assignees: The United States of America as represented by the Secretary of the Navy; The Regents of the University of Michigan
- Inventors: Carl H. June; Craig B. Thompson; Suil Kim
- Web page: https://patentgrep.com/patent/US20040203155A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- G11B 2220/20: Disc-shaped record carriers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G11B: INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER (recording measured values in a way that does not require playback through a transducer G01D9/00; recording or playback apparatus using mechanically marked tape, e.g. punched paper tape, or using unit records, e.g. punched or magnetically marked cards G06K; transferring data from one type of record carrier to another G06K1/18; circuits for coupling output of reproducer to radio receiver H04B1/20; gramophone pick-ups or like acoustic electromechanical transducers or circuits therefor H04R)

## Abstract

A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.

## Claims

### Claim at position 1

1-21. (Cancelled)

### Claim 22

A method for increasing the expression of an exogenous nucleic acid molecule in T cells, comprising
(a) contacting the T cells in vitro with at least one stimulatory agent; and
(b) introducing the exogenous nucleic acid molecule into the T cells from step (a) in vitro, less than about 24 hours after contacting of said T cells,
such that the expression of the exogenous nucleic acid molecule is increased in the T cells; and
wherein said exogenous nucleic acid molecule is introduced into the T cells using a viral vector.

### Claim 23 (depends on 22)

The method of claim 22 wherein the viral vector is selected from the group consisting of recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1.

### Claim 24 (depends on 22)

The method of claim 22 wherein the viral vector is a recombinant retrovirus.

### Claim 25 (depends on 24)

The method of claim 24 wherein the recombinant retrovirus is replication defective.

### Claim 26 (depends on 22)

The method of claim 22, wherein the T cells are primary T cells.

### Claim 27 (depends on 22)

The method of claim 22 wherein the at least one stimulatory agent is a super-antigen, a combination of a phorbol ester and a calcium ionophore, or comprises a protein tyrosine kinase activator.

### Claim 28 (depends on 22)

The method of claim 22, wherein the at least one stimulatory agent is an antibody or an antigen binding fragment thereof.

### Claim 29 (depends on 22)

The method of claim 22, wherein the at least one stimulatory agent interacts with the T cell receptor/CD3 complex.

### Claim 30 (depends on 29)

The method of claim 29 wherein the at least one stimulatory agent is an anti-CD3 antibody or a fragment thereof.

### Claim 31 (depends on 22)

The method of claim 22 wherein the at least one stimulatory agent interacts with a CD2 molecule on the T cells.

### Claim 32 (depends on 22)

The method of claim 22 wherein the at least one stimulatory agent is an antigen presented by an antigen presenting cell.

### Claim 33 (depends on 22)

The method of claim 22 wherein the at least one stimulatory agent is an anti-CD28 antibody or a fragment thereof.

### Claim 34 (depends on 22)

The method of claim 22 wherein the at least one stimulatory agent is a stimulatory form of a natural ligand of CD28.

### Claim 35 (depends on 34)

The method of claim 34 wherein the stimulatory form of a natural ligand of CD28 is B7-1 or B7-2.

### Claim 36 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 22 to 32 wherein the at least one stimulatory agent is attached to a surface.

### Claim 37 (depends on 36)

The method of claim 36 wherein the surface is a bead, a tissue culture dish, or a cell surface.

### Claim 38 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 22 to 37 wherein said nucleic acid molecule is introduced into said T cells between approximately 1 and less than 24 hours after stimulation of said T cells.

### Claim 39 (depends on 38)

The method of claim 38 wherein said nucleic acid molecule is introduced into said T cells approximately 10 hours after stimulation of said T cells.

### Claim 40 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 22 to 37 wherein the T cells are further stimulated in vitro to increase their number.

### Claim 41

A method for increasing the expression of an exogenous nucleic acid molecule in T cells, comprising:
(a) contacting the T cells in vitro with at least one stimulatory agent, wherein the at least one stimulatory agent is a combination of a first agent which provides a primary activation signal to the T cells and a second agent which provides a costimulatory signal to the T cells; and
(b) introducing an exogenous nucleic acid molecule into the T cells from step (a) in vitro less than about 24 hours after contacting of said T cells,
such that the expression of the exogenous nucleic acid molecule is increased in the T cells; and
wherein said exogenous nucleic acid molecule is introduced into the T cells using a viral vector.

### Claim 42 (depends on 41)

The method of claim 41 wherein the viral vector is selected from the group consisting of recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1.

### Claim 43 (depends on 41)

The method of claim 41 wherein the viral vector is a recombinant retrovirus.

### Claim 44 (depends on 43)

The method of claim 43 wherein the recombinant retrovirus is replication defective.

### Claim 45 (depends on 41)

The method of claim 41 wherein the T cells are primary T cells.

### Claim 46 (depends on 41)

The method of claim 41 wherein the first agent interacts with the T cell receptor/CD3 complex.

### Claim 47 (depends on 46)

The method of claim 46 wherein the first agent is an anti-CD3 antibody or a fragment thereof.

### Claim 48 (depends on 41)

The method of claim 41 wherein the first agent interacts with a CD2 molecule on the T cells.

### Claim 49 (depends on 41)

The method of claim 41 wherein the first agent is an antigen presented by an antigen presenting cell.

### Claim 50 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 41-49 wherein the second agent is an anti-CD28 antibody or a fragment thereof.

### Claim 51 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 41-49 wherein the second agent is a stimulatory form of a natural ligand of CD28.

### Claim 52 (depends on 45)

The method of claim 45 wherein the stimulatory form of a natural ligand of CD28 is B7-1 or B7-2.

### Claim 53 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 41-48 wherein the first agent or the second agent is an antibody.

### Claim 54 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 41-48 wherein the first agent and the second agent are antibodies.

### Claim 55 (depends on 54)

The method of claim 54 wherein the first agent and the second agent are attached to a surface.

### Claim 56 (depends on 55)

The method of claim 55 wherein the surface is a bead, a tissue culture dish or a cell surface.

### Claim 57 (depends on 55)

The method of claim 55 wherein the surface is a bead.

### Claim 58 (depends on 55)

The method of claim 55 wherein the T cells are further stimulated in vitro to increase their number.
